GSK621659A | 475489-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: GSK621659A
• CAS: 475489-15-7
• 化学式: C₂₈H₃₁N₅O
• 分子量: 453.587
• InChiKey: LSFLAQVDISHMNB-DKXQDJALSA-N

物化性质

• 沸点：
  677.5±55.0 °C(Predicted)
• 密度：
  1.31

计算性质

• 辛醇/水分配系数(LogP)：
  5.31
• 重原子数：
  34.0
• 可旋转键数：
  7.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  69.2
• 氢给体数：
  1.0
• 氢受体数：
  6.0

文献信息

• [EN] 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE
  申请人：NOVARTIS AG

  公开号：WO2002092599A1

  公开（公告）日：2002-11-21

  The invention relates to new 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof-alone or in combination with one or more other pharmaceutically active compounds-for the treatment of a disease, especially a proliferative disease, such as a tumour disease, a method for the treatment of such diseases in mammals, especially in humans, and the use of such a compound-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of a pharmaceutical composition (medicament) for the treatment especially of a proliferative disease, such as a tumour.

  本发明涉及新的4-氨基-5-苯基-7-环丁基吡咯并[2,3-d]嘧啶衍生物，其制备方法，其在用于治疗人体或动物体的过程中的应用，其独自使用或与一个或多个其他药物活性化合物结合用于治疗疾病，特别是增生性疾病，如肿瘤疾病，哺乳动物，特别是人类的这种疾病的治疗方法，以及这种化合物的使用-独自使用或与一个或多个其他药物活性化合物结合用于制备用于治疗特别是增生性疾病，如肿瘤的药物组合（药物）。
• 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives
  申请人：——

  公开号：US20040180911A1

  公开（公告）日：2004-09-16

  The invention relates to new 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof-alone or in combination with one or more other pharmaceutically active compounds-for the treatment of a disease, especially a proliferative disease, such as a tumour disease, a method for the treatment of such diseases in mammals, especially in humans, and the use of such a compound-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of a pharmaceutical composition (medicament) for the treatment especially of a proliferative disease, such as a tumour.

  本发明涉及新的4-氨基-5-苯基-7-环丁基吡咯[2,3-d]嘧啶衍生物，其制备方法，其在治疗人体或动物体的过程中的应用，其单独或与一个或多个其他药物活性化合物结合的用于治疗疾病，特别是增生性疾病，如肿瘤疾病的用途，以及在哺乳动物，特别是人类中治疗此类疾病的方法，以及单独或与一个或多个其他药物活性化合物结合的用于制备治疗增生性疾病，如肿瘤的药物组合（药物）的用途。
• CANCER TREATMENT METHOD
  申请人：Rusnak David

  公开号：US20090203718A1

  公开（公告）日：2009-08-13

  The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and an IGF-1R inhibitor to a mammal suffering from a cancer.

  本发明涉及一种治疗哺乳动物癌症的方法和在这种治疗中有用的药物组合。具体来说，该方法涉及一种癌症治疗方法，包括向患有癌症的哺乳动物施用一种Erb家族抑制剂和一种IGF-1R抑制剂。
• Methods and compositions for treating hyperproliferative conditions
  申请人：Stiles Dean Charles

  公开号：US20050215564A1

  公开（公告）日：2005-09-29

  The present invention relates to a combination which comprises (a) an inhibitor of a tissue non-specific growth factor receptor and (b) an inhibitor of a tissue specific growth factor receptor for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of hyperproliferative conditions, such as in particular cancer, in a mammal, particularly a human. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating hyperproliferative conditions, such as especially cancer, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.

  本发明涉及一种组合物，它包括(a)组织非特异性生长因子受体的抑制剂和(b)组织特异性生长因子受体的抑制剂，可同时、并发、单独或依次使用，特别是用于治疗哺乳动物，尤其是人类的过度增殖症，如特别是癌症。本发明还涉及包含这种组合物的药物组合物，以及用这种组合物治疗过度增殖症，如特别是癌症的方法。本发明还进一步涉及包含这种组合物的商业包装或产品。
• 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES
  申请人：Novartis AG

  公开号：EP1390369A1

  公开（公告）日：2004-02-25